Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Reddy

Showing results (1291-1300 of 1,307) with videos related to

Pageof 131
Sort By:
Bone Marrow Transplantation|December 20, 2016
Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR studyR T Maziarz, R Brazauskas, M Chen, et al.
BMJ Public Health|June 16, 2026
What are the initial research priorities for paediatric emergency medicine in India? A prioritisation studyIndumathy Santhanam, Muralidharan Jayashree, Suresh Kumar Angurana, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
Nature|December 15, 2015
Sublimation in bright spots on (1) CeresA Nathues, M Hoffmann, M Schaefer, et al.
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
Science (New York, N.Y.)|September 22, 2012
Pitted terrain on Vesta and implications for the presence of volatilesB W Denevi, D T Blewett, D L Buczkowski, et al.
Nature|November 7, 2012
Dark material on Vesta from the infall of carbonaceous volatile-rich materialT B McCord, J-Y Li, J-P Combe, et al.
Physical Review Letters|February 16, 2024
Evidence of a Hardening in the Cosmic Ray Proton Spectrum at around 166 TeV Observed by the GRAPES-3 ExperimentF Varsi, S Ahmad, M Chakraborty, et al.
Lancet (London, England)|September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaiez Zannad, Christopher M O'Connor, Javed Butler, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Pageof 131

Showing results (1291-1300 of 1,307) with videos related to

Sort By:
Pageof 131
Bone Marrow Transplantation|December 20, 2016
Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR studyR T Maziarz, R Brazauskas, M Chen, et al.
BMJ Public Health|June 16, 2026
What are the initial research priorities for paediatric emergency medicine in India? A prioritisation studyIndumathy Santhanam, Muralidharan Jayashree, Suresh Kumar Angurana, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
Nature|December 15, 2015
Sublimation in bright spots on (1) CeresA Nathues, M Hoffmann, M Schaefer, et al.
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
Science (New York, N.Y.)|September 22, 2012
Pitted terrain on Vesta and implications for the presence of volatilesB W Denevi, D T Blewett, D L Buczkowski, et al.
Nature|November 7, 2012
Dark material on Vesta from the infall of carbonaceous volatile-rich materialT B McCord, J-Y Li, J-P Combe, et al.
Physical Review Letters|February 16, 2024
Evidence of a Hardening in the Cosmic Ray Proton Spectrum at around 166 TeV Observed by the GRAPES-3 ExperimentF Varsi, S Ahmad, M Chakraborty, et al.
Lancet (London, England)|September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaiez Zannad, Christopher M O'Connor, Javed Butler, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025Peter L Greenberg, Richard M Stone, Yasmin Abaza, et al.
Pageof 131